Fluensulfone
(Synonyms: 联氟砜,MCW-2) 目录号 : GC10705
A nematicide
Cas No.:318290-98-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Fluensulfone is identified as a new nematicide for chemical control of plant parasitic nematodes.
Plant parasitic nematodes can infest crops and present a threat to food security. Currently available chemical controls such as methyl bromide, organophosphates as well as carbamates have an unacceptable toxicity level to non-target organisms and are being withdrawn.
In vitro: Previous study showed that the model genetic organism Caenorhabditis elegans was susceptible to the treatment of fluensulfone. While the required dose was higher than that which had nematicidal activity against Meloidogyne spp. In addition, the profile of effects on motility, egg-hatching and survival was similar to that reported for plant parasitic nematodes.C. elegans therefore provided a tractable paradigm to analyze the effects of fluensulfone on nematode behaviour. Moreover, it was also found that fluensulfone had pleiotropic actions and inhibited development, egg-laying, egg-hatching, feeding and locomotion [1].
In vivo: In mice, but not in rats, fluensulfone at high doses has shown an increased incidence of lung adenomas. Moreover, fluensulfone was not genotoxic. In addition, the administration of fluensulfone to mice resulted in an early increase in Clara cell proliferation [2].
Clinical trial: Up to now, fluensulfone is still in the preclinical development stage.
References:
[1] Kearn J,Ludlow E,Dillon J,O'Connor V,Holden-Dye L. Fluensulfone is a nematicide with a mode of action distinct from anticholinesterases and macrocyclic lactones. Pestic Biochem Physiol.2014 Feb;109:44-57.
[2] Strupp C,Banas DA,Cohen SM,Gordon EB,Jaeger M,Weber K. Relationship of metabolism and cell proliferation to the mode of action of fluensulfone-induced mouse lung tumors: analysis of their human relevance using the IPCS framework. Toxicol Sci.2012 Jul;128(1):284-94.
Cell experiment: | For these assays worms of different developmental stages are incubated in liquid with and without Fluensulfone for up to 24 h, and paralysis is scored. 400 μL of M9 phosphate buffer with either Fluensulfone (100 μM, 200 μM or 1 mM) or vehicle (0.5% acetone) is put into each well of a 24 well plate (5 replicates for each Fluensulfone concentration). 5 μL suspension of age synchronised C. elegans (L1, L2/3, L4 or one day old adult) is added to each well. Each well contains approximately 50 to100 worms. The number of worms not moving at 1, 2, 3, 4, 5, 6 and 24 h is determined. The experiment is conducted on two separate occasions with five replicates[1]. |
Animal experiment: | Groups of 10 female specific pathogen-free CD-1 mice each are treated with untreated diet, diet containing 1200 mg/kg Fluensulfone (high dose in carcinogenicity study), or 1305 mg/kg of isoniazid as a positive control substance for 3 or 7 days, respectively. Two and 14 h before sacrifice, the animals are injected ip with 100 μL of a 10 mg/mL aqueous bromodeoxyuridine (BrdU)-solution. Sacrifice by exsanguination under deep irreversible pentobarbital narcosis is performed early in the morning to assure that the animals are exposed to the test item until shortly before sacrifice[2]. |
References: [1]. Kearn J, et al. Fluensulfone is a nematicide with a mode of action distinct from anticholinesterases and macrocyclic lactones. Pestic Biochem Physiol. 2014 Feb;109:44-57. | |
| Cas No. | 318290-98-1 | SDF | |
| 别名 | 联氟砜,MCW-2 | ||
| 化学名 | 5-chloro-2-((3,4,4-trifluorobut-3-en-1-yl)sulfonyl)thiazole | ||
| Canonical SMILES | ClC1=CN=C(S(CC/C(F)=C(F)\F)(=O)=O)S1 | ||
| 分子式 | C7H5ClF3NO2S2 | 分子量 | 291.7 |
| 溶解度 | ≥ 29.2mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4282 mL | 17.1409 mL | 34.2818 mL |
| 5 mM | 0.6856 mL | 3.4282 mL | 6.8564 mL |
| 10 mM | 0.3428 mL | 1.7141 mL | 3.4282 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet